LB54640
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Rhythm · Phase 2 · Completed · Enrollment 28
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Bivamelagon Low dose (200 milligrams [mg]) | n/r | n/r | n/r | n/r | n/r |
| Bivamelagon Middle dose (400 mg) | n/r | n/r | n/r | n/r | n/r |
| Bivamelagon High dose (600 mg) | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
| Open-label Bivamelagon | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.